Table 2:
Sociodemographic and clinical characteristics of cohorts in KS incidence studies
| COHORT, author (year) | Age in years, median (IQR)* | Male PLWH (%) | Race (%) | MSM† (%) | |||
|---|---|---|---|---|---|---|---|
| PLWH | KS+ | PLWH | KS+ | PLWH | KS+ | ||
| UK, Portsmouth (2003) | Mean, KS+=33 (SD: 8.7) | ≈6048 (70%)§ | 1060 (88%) | NR | African (≈15) | NR | NR |
| VA, Kowalkowski (2015) | Mean=45 (SD: 10.4) | 25 529 (100%) | 341 (100%) | White (37). Black (51). Unknown (5). | White (40). Black (50). Unknown (9) | NR | NR |
| COHERE42, COHERE (2017) | 37 (31–44) | 143 617 (69%) | 1779 (67%) | African (10). Latin American (4) | African (7). Latin American (5). | 36% | 62% |
| FHDH, Grabar (2006) | 37 (30–41) | 71% | 95% | Sub-saharan African (9) | Sub-saharan African (4) | 32% | 74% |
| CASCADE, Lodi (2010) | 36 (32–43) | 100% | 100% | NR | NR | 100% | 100% |
| KAISER, Chao (2012) | Mean=40 (SD: 9.8) | 90% | NR | White (54). Black (20). Hispanic (21). Asian (5). Unknown (5) | NR | 62% | NR |
| FHDH-ANRS, Lacombe (2013) | Age 15–34: 38%; 35–49: 46%; ≥50: 16% | 67% | 94% | NR. Sub-saharan African (14%) | NR | 32% | 70% |
| DAD, Bruyand (2015) | 39 (33–46) | 73% | NR | White (50). Black African (7). Other (2). Unknown (41) | NR | 44% | NR |
| COHERE29, COHERE (2016) | 37 (31–45) | 71% | 88% | European/North American (83). African (15). Other (2). | European/North American (83). African (16). Other (1). | 40% | 64% |
| CD4 (cells/μL), median (IQR) | VL (% patients <500 copies/mL) | |||
|---|---|---|---|---|
| Baseline‡ | At KS diagnosis | Timing of measurement | KS+ | KS− |
| NR | 57 (18–152)¶ | NA | NA | NA |
| CD4KS− <200=44%; ≥200=56% | CD4 <200=54%; ≥200=46% | at KS diagnosis/ censor | 29% | 72% |
| 222 (112–344)ǁ | 165 (53–328)** | at KS diagnosis | 32% | NA |
| 202 (69–349) | 52 (14–181) | NA | NR | NR |
| NR | 195 (33–284)¶ | at KS diagnosis | Median=4.8 (IQR: 3.9–4.3) | NA |
| 433 (281–620) | NR | at KS diagnosis/ censor | Mean, all PLWH=4.7 log10 copies/mL (SD: 5.0) | |
| 202 (69–349) | 52 (14–181) | at KS diagnosis | 9.6% | NA |
| Mean=364 (SD: 279) | NR | at baseline | Median, all PLWH=2.3 log10 copies/mL (IQR: 1.7–4.3) | |
| KS−: 250 (124–370) | 300 (154–460)¶ | At cART initiation | 0.3% | 1.4% |
| KS+: 146 (43–302) | At KS diagnosis | 40% | NA | |
aIRR=adjusted incident rate ratio. CASCADE=Concerted Action on Seroconversion to AIDS and Death in Europe. CD4KS−=CD4 in PLWH who did not develop incident KS. COHERE=Collaboration of Observational HIV Epidemiological Research in Europe. CWA=calculated weighted average. DAD=Data collection on Adverse events of Anti-HIV Drugs. FHDH=French Hospital Database on HIV. FHDH-ANRS=FHDH-Agence Nationale, de Recherches sur le SIDA. KS+=PLWH diagnosed with Kaposi sarcoma during study period. MSM=men who have sex with men. NR=not reported. PLWH=people living with HIV. UK=United Kingdom. VL=viral load.
All PLWH unless otherwise noted.
% overall MSM.
Baseline, nadir, and “at enrollment” were treated synonymously, unless the study included pre-cART era, then nadir is reported rather than “at enrollment.”
Calculated using study reported data.
CWA of reported medians of 2 time periods.
CWA of reported medians of 5 continents.
CWA of reported medians of 4 continents (authors excluded Asia).